DrugPatentWatch Database Preview
Mdd Us Company Profile
» See Plans and Pricing
What is the competitive landscape for MDD US, and what generic alternatives to MDD US drugs are available?
MDD US has two approved drugs.
There are three US patents protecting MDD US drugs.
There are eighty patent family members on MDD US drugs in thirty-one countries and eleven supplementary protection certificates in ten countries.
Summary for Mdd Us
| International Patents: | 80 |
| US Patents: | 3 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Mdd Us
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | 8,076,515 | Start Trial | Y | Y | Start Trial | ||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | 8,283,380 | Start Trial | Start Trial | ||||
| Mdd Us | APOKYN | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 021264-002 | Apr 20, 2004 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | 8,278,485 | Start Trial | Y | Start Trial | |||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | 8,076,515 | Start Trial | Y | Y | Start Trial | ||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | Start Trial | Start Trial | |||||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | 8,278,485 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Mdd Us Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | PA05010873 | Start Trial |
| South Korea | 101129015 | Start Trial |
| Denmark | 2474521 | Start Trial |
| Spain | 2326373 | Start Trial |
| China | 101472880 | Start Trial |
| Poland | 2029524 | Start Trial |
| Norway | 2015018 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mdd Us Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1613296 | C20150033 00258 | Estonia | Start Trial | PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015 |
| 1613296 | 132016000023012 | Italy | Start Trial | PRODUCT NAME: SAFINAMIDE(XADAGO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/984, 20150224 |
| 1613296 | 46/2015 | Austria | Start Trial | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| 1613296 | 92782 | Luxembourg | Start Trial | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
| 1613296 | 241 50017-2015 | Slovakia | Start Trial | PRODUCT NAME: SAFINAMID; REGISTRATION NO/DATE: EU/1/14/984/001 - EU/1/14/984/010 20150226 |
| 1613296 | 300752 | Netherlands | Start Trial | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| 1613296 | CR 2015 00042 | Denmark | Start Trial | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
